Novel Tetrahydrocyclohepteneindole Derivatives Targeting Estrogen Receptor Alpha for the Treatment of Breast Cancer

other OA: closed public-domain-us
AI-generated summary by gemini-2.5-flash-lite, 2026-06-13

This patent describes new tetrahydrocyclohepteneindole compounds that selectively inhibit estrogen receptor alpha, showing promise for treating ERα-related conditions like breast cancer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

This patent presents novel substituted tetrahydrocyclohepteneindole derivatives as selective estrogen receptor alpha (ERα) inhibitors. These compounds demonstrate potential for treating Erα-related diseases such as cancers, ovulatory dysfunction, endometriosis, and inflammation diseases.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: pmc

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

SciLite annotations

chemicals 2
benzocycloheptene benzocycloheptene

Source provenance

europepmc
last seen: 2026-08-23T06:15:12.370321+00:00
pmc
last seen: 2026-05-13T20:22:03.195721+00:00
pubmed
last seen: 2026-08-23T06:12:00.391771+00:00
scilite
last seen: 2026-05-18T04:25:29.313245+00:00
unpaywall
last seen: 2026-06-17T06:32:23.968882+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine